Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.

Published

Journal Article

Human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 is targeted by broadly-reactive neutralizing antibodies 2F5 and 4E10, making it an attractive target for vaccine development. To better assess immunogenic properties of gp41, we generated five soluble glutathione S-transferase fusion proteins encompassing C-terminal 30, 64, 100, 142, or 172 (full-length) amino acids of gp41 ectodomain from M group consensus envelope sequence. Antibody responses in HIV-1-infected patients were evaluated using these proteins and overlapping peptides. We found (i) antibody responses against different regions of gp41 varied tremendously among individual patients, (ii) patients with stronger antibody responses against membrane-proximal external region exhibit broader and more potent neutralizing activity, and (iii) several patients mounted antibodies against epitopes that are near, or overlap with, those targeted by 2F5 or 4E10. These soluble gp41 fusion proteins could be an important source of antigens for future vaccine development efforts.

Full Text

Duke Authors

Cited Authors

  • Penn-Nicholson, A; Han, DP; Kim, SJ; Park, H; Ansari, R; Montefiori, DC; Cho, MW

Published Date

  • March 2008

Published In

Volume / Issue

  • 372 / 2

Start / End Page

  • 442 - 456

PubMed ID

  • 18068750

Pubmed Central ID

  • 18068750

Electronic International Standard Serial Number (EISSN)

  • 2514-4138

International Standard Serial Number (ISSN)

  • 1096-0341

Digital Object Identifier (DOI)

  • 10.1016/j.virol.2007.11.009

Language

  • eng